Orchid to launch products in EU market
Chennai, Aug 4 (UNI) The city-based generic pharma major Orchid Chemicals and Pharmaceuticals Limited today announced that it has received approvals of its Marketing Authorisation (MA) for Piperacillin and Tazobactam for Injection for marketing in the EU countries.
Orchid filed the MA for this product with the UK MHRA through the DCP (De-Centralised Procedure) route enabling the company to launch the product across the EU countries, a company release said here.
"This is a very important milestone in our regulated generics plan. Through this approval, we are expanding into a new product range of premium Penicillin Injectables and also foraying into the EU generics market,'' Mr K Raghavendra, Company Managing Director, said.
''We are launching this product through our exclusive marketing alliance with Hospira for the EU market and given the limited competition envisaged in this product. We are confident of a robust market share and revenue stream," he added.
The company achieved a total income of Rs 306.33 crore for the quarter ended June 30, 2008 in comparison to Rs 236.27 crore registered during the corresponding first quarter of the last fiscal, growing by 29.6 per cent.
Earnings
Before
Interest
and
Tax
(EBIT)
was
Rs
57.16
crore
compared
to
Rs
43.23
crore
during
the
corresponding
quarter
of
the
last
year.
The
profit
before
exceptional
item
and
tax
was
Rs
26.91
crore
as
against
Rs
23.05
crore
of
the
Q1
of
the
last
fiscal.
UNI
WS
DS
1641